Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy.
MRD
early stage follicular lymphoma
radiotherapy
rituximab
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
10
01
2019
accepted:
21
05
2019
pubmed:
7
8
2019
medline:
6
8
2020
entrez:
7
8
2019
Statut:
ppublish
Résumé
Since 2000, we have investigated 67 consecutive patients with stage I/II follicular lymphoma (FL) for the presence of BCL2/IGH rearrangements by polymerase chain reaction (PCR), real time quantitative PCR (RQ-PCR) and digital droplet PCR (ddPCR). All patients were treated with involved-field radiotherapy (IF-RT) (24-30 Gy). From 2005, patients with minimal residual disease (MRD) after IF-RT received rituximab (R) (375 mg/m
Substances chimiques
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
249-258Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro (AIRC)
Pays : International
Organisme : Molecular Clinical Oncology MCO
ID : 10007
Pays : International
Organisme : Metastases Special Program
ID : 21198
Pays : International
Organisme : Progetti di Rilevante Interesse Nazionale (PRIN)
ID : 2015ZMRFEA
Pays : International
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 British Society for Haematology and John Wiley & Sons Ltd.
Références
Al-Hamadani, M., Habermann, T.M., Cerhan, J.R., Macon, W.R., Maurer, M.J. & Go, R.S. (2015) Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. American Journal of Hematology, 90, 790-795.
Anderson, J.R., Armitage, J.O. & Weisenburger, D.D. (1998) Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 9, 717-720.
Armitage, J.O. & Weisenburger, D.D. (1998) New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. Journal of Clinical Oncology, 16, 2780-2795.
Barzenje, D.A., Cvancarova Smastuen, M., Liestol, K., Fossa, A., Delabie, J., Kolstad, A. & Holte, H. (2015) radiotherapy compared to other strategies in the treatment of stage I/II follicular lymphoma: a study of 404 patients with a median follow-up of 15 years. PLoS One, 10, e0131158.
Campbell, B.A., Voss, N., Woods, R., Gascoyne, R.D., Morris, J., Pickles, T., Connors, J.M. & Savage, K.J. (2010) Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer, 116, 3797-3806.
Cavalli, M., De Novi, L.A., Della Starza, I., Cappelli, L.V., Nunes, V., Pulsoni, A., Del Giudice, I., Guarini, A. & Foa, R. (2017) Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma. British Journal of Haematology, 177, 588-596.
Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M., Diehl, V.; for the International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
Delgado, J., Pereira, A., Villamor, N., López-Guillermo, A. & Rozman, C. (2014) Survival analysis in hematologic malignancies: recommendations for clinicians. Haematologica, 99, 1410-1420.
Della Starza, I., Del Giudice, I., Menale, L., Cappelli, L.V., Cavalli, M., De Novi, L.A., Apicella, V., Soscia, R., Cafforio, L., Mariglia, P., Chiaretti, S., Vitale, A., Guarini, A. & Foà, R. (2018) Minimal residual disease (MRD) detection by digital-droplet-pcr (ddPCR) in lymphoid malignancies. Haematologica, 103, S1-S129.
Drandi, D., Kubiczkova-Besse, L., Ferrero, S., Dani, N., Passera, R., Mantoan, B., Gambella, M., Monitillo, L., Saraci, E., Ghione, P., Genuardi, E., Barbero, D., Omede, P., Barberio, D., Hajek, R., Vitolo, U., Palumbo, A., Cortelazzo, S., Boccadoro, M., Inghirami, G. & Ladetto, M. (2015) Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma: a comparison with real-time PCR. The Journal of Molecular Diagnostics, 17, 652-660.
Dreyling, M., Ghielmini, M., Rule, S., Salles, G., Vitolo, U., Ladetto, M. & Committee, E.G. (2016) Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 27, v83-v90.
Freedman, A. (2014) Follicular lymphoma: 2014 update on diagnosis and management. American Journal of Hematology, 89, 429-436.
Friedberg, J.W., Byrtek, M., Link, B.K., Flowers, C., Taylor, M., Hainsworth, J., Cerhan, J.R., Zelenetz, A.D., Hirata, J. & Miller, T.P. (2012) Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. Journal of Clinical Oncology, 30, 3368-3375.
Galimberti, S., Luminari, S., Ciabatti, E., Grassi, S., Guerrini, F., Dondi, A., Marcheselli, L., Ladetto, M., Piccaluga, P.P., Gazzola, A., Mannu, C., Monitillo, L., Mantoan, B., Del Giudice, I., Della Starza, I., Cavalli, M., Arcaini, L., Tucci, A., Palumbo, G.A., Rigacci, L., Pulsoni, A., Vitolo, U., Boccomini, C., Vallisa, D., Bertoldero, G., Gaidano, G., Musto, P., Petrini, M. & Federico, M. (2014) Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. Clinical Cancer Research, 20, 6398-6405.
Gribben, J.G., Freedman, A.S., Neuberg, D., Roy, D.C., Blake, K.W., Woo, S.D., Grossbard, M.L., Rabinowe, S.N., Coral, F., Freeman, G.J., Ritz, J. & Nadler, L.M. (1991) Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. New England Journal of Medicine, 325, 1525-1533.
Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., Reiser, M., Metzner, B., Harder, H., Hegewisch-Becker, S., Fischer, T., Kropff, M., Reis, H.E., Freund, M., Wormann, B., Fuchs, R., Planker, M., Schimke, J., Eimermacher, H., Trumper, L., Aldaoud, A., Parwaresch, R. & Unterhalt, M. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106, 3725-3732.
Hirt, C., Schuler, F., Kiefer, T., Schwenke, C., Haas, A., Niederwieser, D., Neser, S., Assmann, M., Srock, S., Rohrberg, R., Dachselt, K., Leithauser, M., Rabkin, C.S., Herold, M. & Dolken, G. (2008) Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients. British Journal of Haematology, 141, 631-640.
Janikova, A., Bortlicek, Z., Campr, V., Kopalova, N., Benesova, K., Belada, D., Prochazka, V., Pytlik, R., Vokurka, S., Pirnos, J., Duras, J., Mocikova, H., Mayer, J. & Trneny, M. (2015) Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy? Leukaemia & Lymphoma, 56, 2350-2356.
Klein, U. & Dalla-Favera, R. (2008) Germinal centres: role in B-cell physiology and malignancy. Nature Reviews Immunology, 8, 22-33.
Kluin, P.M. (2013) Origin and migration of follicular lymphoma cells. Haematologica, 98, 1331-1333.
Ladetto, M., Sametti, S., Donovan, J.W., Ferrero, D., Astolfi, M., Mitterer, M., Ricca, I., Drandi, D., Corradini, P., Coser, P., Pileri, A., Gribben, J.G. & Tarella, C. (2001) A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. Experimental Hematology, 29, 183-193.
Ladetto, M., Lobetti-Bodoni, C., Mantoan, B., Ceccarelli, M., Boccomini, C., Genuardi, E., Chiappella, A., Baldini, L., Rossi, G., Pulsoni, A., Di Raimondo, F., Rigacci, L., Pinto, A., Galimberti, S., Bari, A., Rota-Scalabrini, D., Ferrari, A., Zaja, F., Gallamini, A., Specchia, G., Musto, P., Rossi, F.G., Gamba, E., Evangelista, A., Vitolo, U. & Fondazione Italiana, L. (2013) Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood, 122, 3759-3766.
Lowry, L., Smith, P., Qian, W., Falk, S., Benstead, K., Illidge, T., Linch, D., Robinson, M., Jack, A. & Hoskin, P. (2011) Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiotherapy and Oncology, 100, 86-92.
Luminari, S., Galimberti, S., Versari, A., Biasoli, I., Anastasia, A., Rusconi, C., Ferrari, A., Petrini, M., Manni, M. & Federico, M. (2016) Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. Haematologica, 101, e66-8.
Mac Manus, M.P. & Hoppe, R.T. (1996) Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. Journal of Clinical Oncology, 14, 1282-1290.
MacManus, M., Fisher, R., Roos, D., O'Brien, P., Macann, A., Davis, S., Tsang, R., Christie, D., McClure, B., Joseph, D., Jayamohan, J. & Seymour, J.F. (2018) Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03. Journal of Clinical Oncology, 36, 2918-2925.
Mamessier, E., Broussais-Guillaumot, F., Chetaille, B., Bouabdallah, R., Xerri, L., Jaffe, E.S. & Nadel, B. (2014) Nature and importance of follicular lymphoma precursors. Haematologica, 99, 802-810.
von Neuhoff, N., Dreger, P., Suttorp, M., Marget, M., Kell, S. & Schmitz, N. (1998) Comparison of different strategies of molecular genetic monitoring following autologous stem cell transplantation in patients with follicular lymphoma. Bone Marrow Transplantation, 22, 161-166.
Pugh, T.J., Ballonoff, A., Newman, F. & Rabinovitch, R. (2010) Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis. Cancer, 116, 3843-3851.
Pulsoni, A., Starza, I.D., Frattarelli, N., Ghia, E., Carlotti, E., Cavalieri, E., Matturro, A., Tempera, S., Rambaldi, A. & Foa, R. (2007) Stage I/II follicular lymphoma: spread of bcl-2/IgH+ cells in blood and bone marrow from primary site of disease and possibility of clearance after involved field radiotherapy. British Journal of Haematology, 137, 216-220.
Rambaldi, A., Carlotti, E., Oldani, E., Della Starza, I., Baccarani, M., Cortelazzo, S., Lauria, F., Arcaini, L., Morra, E., Pulsoni, A., Rigacci, L., Rupolo, M., Zaja, F., Zinzani, P.L., Barbui, T. & Foa, R. (2005) Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. Blood, 105, 3428-3433.
Reynders, K., Illidge, T., Siva, S., Chang, J.Y. & De Ruysscher, D. (2015) The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treatment Reviews, 41, 503-510.
Roulland, S., Lebailly, P., Lecluse, Y., Heutte, N., Nadel, B. & Gauduchon, P. (2006) Long-term clonal persistence and evolution of t(14;18)-bearing B cells in healthy individuals. Leukemia, 20, 158-162.
Ruella, M., Filippi, A.R., Bruna, R., Di Russo, A., Magni, M., Caracciolo, D., Passera, R., Matteucci, P., Di Nicola, M., Corradini, P., Parvis, G., Gini, G., Olivieri, A., Ladetto, M., Ricardi, U., Tarella, C. & Devizzi, L. (2016) Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: results of a multicenter study. International Journal of Radiation Oncology Biology Physics, 94, 783-791.
Sancho, J.M., Garcia, O., Mercadal, S., Pomares, H., Fernandez-Alvarez, R., Gonzalez-Barca, E., Tapia, G., Gonzalez-Garcia, E., Moreno, M., Domingo-Domenech, E., Sorigue, M., Navarro, J.T., Motllo, C., Fernandez-de-Sevilla, A., Feliu, E. & Ribera, J.M. (2015) The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment. Leukemia Research, 39, 853-858.
Solal-Céligny, P., Roy, P., Colombat, P., White, J., Armitage, J.O., Arranz-Saez, R., Au, W.Y., Bellei, M., Brice, P., Caballero, D., Coiffier, B., Conde-Garcia, E., Doyen, C., Federico, M., Fisher, R.I., Garcia-Conde, J.F., Guglielmi, C., Hagenbeek, A., Haïoun, C., LeBlanc, M., Lister, A.T., Lopez-Guillermo, A., McLaughlin, P., Milpied, N., Morel, P., Mounier, N., Proctor, S.J., Rohatiner, A., Smith, P., Soubeyran, P., Tilly, H., Vitolo, U., Zinzani, P., Zucca, E. & Montserrat, E. (2004) Follicular lymphoma international prognostic index. Blood, 104, 1258-1265.
Vargo, J.A., Gill, B.S., Balasubramani, G.K. & Beriwal, S. (2015) What is the optimal management of early-stage low-grade follicular lymphoma in the modern era? Cancer, 121, 3325-3334.
van der Velden, V.H., Cazzaniga, G., Schrauder, A., Hancock, J., Bader, P., Panzer-Grumayer, E.R., Flohr, T., Sutton, R., Cave, H., Madsen, H.O., Cayuela, J.M., Trka, J., Eckert, C., Foroni, L., Zur Stadt, U., Beldjord, K., Raff, T., van der Schoot, C.E., van Dongen, J.J.; for the European Study Group on MRD detection in ALL (ESG-MRD-ALL). (2007) Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia, 21, 604-611.
Weinberg, O.K., Ai, W.Z., Mariappan, M.R., Shum, C., Levy, R. & Arber, D.A. (2007) "Minor" BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases. The Journal of Molecular Diagnostics, 9, 530-537.
Wennekes, L., Ottevanger, P.B., Raemaekers, J.M., Schouten, H.C., de Kok, M.W., Punt, C.J., Grol, R.P., Wollersheim, H.C. & Hermens, R.P. (2011) Development and measurement of guideline-based indicators for patients with non-Hodgkin's lymphoma. Journal of Clinical Oncology, 29, 1436-1444.
Witzens-Harig, M., Hensel, M., Unterhalt, M. & Herfarth, K. (2011) Treatment of limited stage follicular lymphoma with rituximab immunotherapy and involved field radiotherapy in a prospective multicenter phase II trial-MIR trial. BMC Cancer, 11, 87.